ANDA 80429, held by Bionpharma. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 80429 (Anestacon), held by Bionpharma, was first approved by FDA on Apr 11, 1974, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 11, 1974 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Anestacon2% · jelly;topical | Lidocaine Hydrochloride | Discontinued |
| Nov 4, 2024 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 4, 2024 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jan 16, 1996 | Supplement 18Manufacturing | Approved | None posted |
| May 12, 1992 | Supplement 17Manufacturing | Approved | None posted |
| Jun 12, 1991 | Supplement 14Labeling | Approved | None posted |
| Jun 5, 1991 | Supplement 13Manufacturing | Approved | None posted |
| Feb 16, 1984 | Supplement 11Manufacturing | Approved | None posted |
| Dec 13, 1983 | Supplement 10Manufacturing | Approved | None posted |
| Dec 8, 1983 | Supplement 7Manufacturing | Approved | None posted |
| Apr 11, 1974 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters